UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Annals of oncology, 2015-06, Vol.26 (6), p.1188-1194

2015

Volltextzugriff (PDF)

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Annals of oncology, 2016-05, Vol.27 (5), p.843-849

2016

Volltextzugriff (PDF)

Access of the oncologic patients to the emergency room of the local hospital during the three-year period 2014–2016

Annals of oncology, 2017-10, Vol.28, p.vi99-vi99

2017

Volltextzugriff (PDF)

Drug Delivery in Dermatology: Fundamental and Practical Applications

1st ed. 2021., 2021

Volltextzugriff (PDF)

G187(P) Training together to improve paediatric palliative care through interprofessional simulation

Archives of disease in childhood, 2020-10, Vol.105 (Suppl 1), p.A66-A66

2020

Volltextzugriff (PDF)

Treatment in advanced malignant pleural mesothelioma after chemotherapy standard

Annals of oncology, 2016-09, Vol.27, p.iv15

2016

Volltextzugriff (PDF)

Integrated regimen therapeutic (polybiologic-chemotherapy) for melanoma advanced

European journal of cancer supplements, 2008-10, Vol.6 (14), p.135-135

2008

Volltextzugriff (PDF)

Malignant pleural mesothelioma: Scheme therapeutic after standard treatment (study of phase II)

European journal of cancer supplements, 2008-10, Vol.6 (14), p.150-150

2008

Volltextzugriff (PDF)

Treatment in metastatic prostate cancer with hormone refractory

European journal of cancer supplements, 2008-10, Vol.6 (14), p.1-1

2008

Volltextzugriff (PDF)

A metronomic treatment with oral chemotherapy in patients elderly with metastatic breast cancer

European journal of cancer supplements, 2008-10, Vol.6 (14), p.116-117

2008

Volltextzugriff (PDF)

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

The lancet oncology, 2020-04, Vol.21 (4), p.497-507

2020

Volltextzugriff (PDF)

Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study

Annals of internal medicine, 2018-12, Vol.169 (11), p.741

2018

Volltextzugriff (PDF)

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial

Lung cancer (Amsterdam, Netherlands), 2001-10, Vol.34 (1), p.115-123

2001

Volltextzugriff (PDF)

Cognitive and neural mechanisms underlying semantic ambiguity resolution

Vitello, S

2014

Volltextzugriff (PDF)

518PFOLFOXIRI WITH OR WITHOUT BEVACIZUMAB (BEV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A PROPENSITY SCORE-BASED ANALYSIS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv175-iv176

2014

Volltextzugriff (PDF)

Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis

Annals of oncology, 2014-09, Vol.25, p.iv175

2014

Volltextzugriff (PDF)

DPYD c.1905 + 1G > A and c.2846A > T and UGT1A128 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer

Annals of oncology, 2015-10, Vol.26, p.vi38

2015

Volltextzugriff (PDF)

Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study

Annals of oncology, 2014-06, Vol.25, p.ii107-ii107

2014

Volltextzugriff (PDF)

Inclusive schooling: National and international perspectives

1998

Volltextzugriff (PDF)

Memory B cell subpopulations in the aged

Rejuvenation research, 2006-03, Vol.9 (1), p.149-152

2006

Volltextzugriff (PDF)

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

Neurology, 2011-11, Vol.77 (21), p.1887-1895

2011

Volltextzugriff (PDF)

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

Annals of oncology, 2015-06, Vol.26 (6), p.1188

2015

Volltextzugriff (PDF)

The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics

JMIR research protocols, 2017-12, Vol.6 (12), p.e222-e222

2017

Volltextzugriff (PDF)

The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3513-3513

2006

Volltextzugriff (PDF)

1 – 25 von 1.932

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(591)
Mit Volltextzugriff
(1.365)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The New York Times
(723)
Daily Herald
(268)
Juxtapoz
(73)
Biochemistry
(25)
Propellants, Explosives, Pyrotechnics
(25)
The Journal Of Cardiovascular Nursing
(23)
Digestive And Liver Disease
(14)
New York Times
(14)
Surgical & Cosmetic Dermatology
(14)
Comparative Connections
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

Access of the oncologic patients to the emergency room of the local hospital during the three-year period 2014–2016

Drug Delivery in Dermatology: Fundamental and Practical Applications

G187(P) Training together to improve paediatric palliative care through interprofessional simulation

Treatment in advanced malignant pleural mesothelioma after chemotherapy standard

Integrated regimen therapeutic (polybiologic-chemotherapy) for melanoma advanced

Malignant pleural mesothelioma: Scheme therapeutic after standard treatment (study of phase II)

Treatment in metastatic prostate cancer with hormone refractory

A metronomic treatment with oral chemotherapy in patients elderly with metastatic breast cancer

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial

Outcomes After Endovascular Therapy With Procedural Sedation vs General Anesthesia in Patients With Acute Ischemic Stroke: The AMETIS Randomized Clinical Trial

Cognitive and neural mechanisms underlying semantic ambiguity resolution

518PFOLFOXIRI WITH OR WITHOUT BEVACIZUMAB (BEV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A PROPENSITY SCORE-BASED ANALYSIS

Folfoxiri with or Without Bevacizumab (Bev) As First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): a Propensity Score-Based Analysis

DPYD c.1905 + 1G > A and c.2846A > T and UGT1A128 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer

Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study

Inclusive schooling: National and international perspectives

Memory B cell subpopulations in the aged

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics

The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

Suchergebnisse filtern